Key Points
- Mineralys Therapeutics director Daphne Karydas sold 3,000 shares at an average price of $28.58, generating $85,740. The Rule 10b5-1 plan transaction reduced her direct holdings by 32.61% to 6,200 shares.
- MLYS recently reported a quarterly loss of $2.85 per share, missing the consensus estimate of a $0.55 loss; analysts expect a full-year loss of $4.45 per share.
- Despite mixed analyst opinions, the stock has a consensus “Moderate Buy” rating and a $48.80 target price. Institutional investors own 84.46% of the company, while shares recently traded near $27.98.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the sale, the director directly owned 6,200 shares of the company's stock, valued at $177,196. This represents a 32.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mineralys Therapeutics Stock Performance
Shares of Mineralys Therapeutics stock opened at $27.98 on Friday. The firm has a fifty day moving average of $27.13 and a two-hundred day moving average of $27.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -6.60 and a beta of 0.68. Mineralys Therapeutics, Inc. has a 52 week low of $22.30 and a 52 week high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). As a group, equities research analysts predict that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Timothy G. Youngquist 2020 Irrevocable Trust bought a new stake in shares of Mineralys Therapeutics in the second quarter worth about $2,721,000. TimesSquare Capital Management LLC bought a new position in shares of Mineralys Therapeutics during the 2nd quarter valued at about $6,363,000. Bank of America Corp DE lifted its holdings in shares of Mineralys Therapeutics by 11.5% during the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company's stock valued at $29,809,000 after purchasing an additional 113,092 shares in the last quarter. Man Group plc acquired a new position in shares of Mineralys Therapeutics in the 2nd quarter valued at approximately $1,609,000. Finally, Artia Global Partners LP grew its position in shares of Mineralys Therapeutics by 143.5% in the 4th quarter. Artia Global Partners LP now owns 137,800 shares of the company's stock valued at $5,001,000 after purchasing an additional 81,200 shares during the period. 84.46% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on MLYS. Jefferies Financial Group restated a "hold" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. HC Wainwright restated a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, Zacks Research raised shares of Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, September 11th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Mineralys Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.80.
Get Our Latest Research Report on Mineralys Therapeutics
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company's research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.
Mineralys' lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
